Michael Nannizzi

Director at Syntis BIO

Capital raised by Syntis BIO

$31.3M+$25.0M latest round

2 Form D filings · first filed Dec 2024 · Boston, MA

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 2
FOUNDED: 2022
30D INTEREST: —

Career

1 company on file · founded 2022

Syntis BIOBiotech · Boston, MAsince 2022

Director

Listed on Syntis BIO's Form D filings

Company filings

via EDGAR · Form D for Syntis BIO2

DateCompanyFormAmountRole on filing

Jun 17, 2025Syntis BIOForm D+$25.0M—

Form DJun 17, 2025 · Syntis BIO+$25.0Mnot a signer

Dec 30, 2024Syntis BIOForm D+$6.3M—

Form DDec 30, 2024 · Syntis BIO+$6.3Mnot a signer

Overview

Last filing Jun 17, 2025

Michael Nannizzi is on file as Director at Syntis BIO in Boston, MA. Syntis BIO has 2 Form D filings on record, $31.3M raised in total.

Teammates

Syntis BIO · 1

Rahul DhandaChief Executive OfficerSigner

Products

Syntis BIO · 1

SYNT-101Oral Therapeutic Platform

SYNT-101 is an innovative oral pill designed to adjust the small intestine's role in metabolism, mimicking the effects of gastric bypass surgery to aid in weight loss management.